<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969211</url>
  </required_header>
  <id_info>
    <org_study_id>VP-VHX-896-1101</org_study_id>
    <nct_id>NCT04969211</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers</brief_title>
  <official_title>An Open-Label, Two-Period, Randomized, Single Oral Dose, Crossover Study to Evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanda Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, two-period, randomized study to evaluate the Bioequivalence of&#xD;
      VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence between VHX-896 tablets relative to iloperidone tablets</measure>
    <time_frame>96 hours</time_frame>
    <description>as measured by plasma concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Safety and Tolerability of a single dose of VHX-896</measure>
    <time_frame>17 days</time_frame>
    <description>As measured by the incidence of adverse events and clinically significant changes in laboratory values, ECG parameters, and vital signs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence A: VHX-896 then iloperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B: Iloperidone then VHX-896</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VHX-896 and iloperidone</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Sequence A: VHX-896 then iloperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloperidone and VHX-896</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Sequence B: Iloperidone then VHX-896</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and/or female participants between 18 to 55 years (inclusive).&#xD;
&#xD;
          -  Have a Body Mass Index (BMI) of &gt; 18.0 and &lt; 30.0 kg/m2; (BMI = weight (kg)/ [height&#xD;
             (m)]2).&#xD;
&#xD;
          -  Good health as determined by no clinically significant deviations from normal in&#xD;
             medical history, clinical laboratory determination, ECGs, and physical examinations&#xD;
             conducted during the screening visit.&#xD;
&#xD;
          -  Participants with no clinically significant medical, psychiatric or sleep disorders as&#xD;
             determined by the PI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with history of drug or alcohol abuse within the 12 months prior to&#xD;
             dosing or evidence of such abuse as indicated by the laboratory assays conducted&#xD;
             during the screening or baseline evaluations.&#xD;
&#xD;
          -  Participants who suffered from significant physical illness (required hospitalization)&#xD;
             in the 4-week period preceding baseline will be excluded.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vanda Pharmaceuticals Inc.</last_name>
    <phone>202-734-3400</phone>
    <email>VHX896@vandapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanda Pharmaceuticals Inc.</last_name>
      <phone>202-734-3400</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iloperidone</keyword>
  <keyword>VHX-896</keyword>
  <keyword>Bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

